CD8A and neoplasm: For instance, CD4+ T cells have been demonstrated to directly lyse tumour cells, possess enhanced in vivo persistence relative to CD8+ T cells and in some models, elicit superior anti-tumour activity compared with CD8+ T cells39–42.